Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Renal failure in multiple myeloma: a medical emergency

Abstract

Up to 50% of newly diagnosed plasma cell myeloma (PCM) patients can present with renal insufficiency, 20% with severe renal impairment and 10% requiring dialysis. PCM patients account for 2% of the dialysis population, adding 5000 new patients each year worldwide. Dialysis-dependent PCM patients have a 2.77 higher risk of death compared with other dialysis-dependent patients without this diagnosis. Renal failure and especially dialysis dependency is an independent poor prognostic factor in PCM, with the majority unable to achieve dialysis independence. Renal failure in PCM is a medical emergency with the need for rapid accurate diagnosis and prompt institution of supportive care and PCM-directed therapy, because reversal of renal impairment and recovery from dialysis dependency can occur in up to half the patients early in the course of disease and can lead to enormous survival benefits. Recently, the serum free light chain (SFLC) assay and serum β-2-microglobulin free heavy chain (SFHC) assay have been used to rapidly diagnose PCM in renal failure and provide prognostic information in the setting of renal failure where the Durie–Salmon and International Staging Systems do not. A renal biopsy early in the course of renal impairment can provide diagnostic and prognostic information. A new generation of dialyzers with larger pores than routine dialyzers can be used with extended hemodialysis to remove SFLC more efficiently than plasmapheresis, allowing for greater renal recovery. Novel chemotherapy agents such as bortezomib are associated with an improved renal response and have moved to the front line of therapy. Successful use of high-dose therapy and autologous hematopoietic cell transplantation (HCT) in PCM with renal failure and even dialysis dependency has been associated with late renal recovery and also allowed for the subsequent use of renal transplantation to provide even greater survival benefits. Combined non-myeloablative allogeneic HCT with renal transplant in PCM patients with end-stage renal disease on dialysis is now being studied in prospective trials.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de Meester J et al. Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrol Dial Transplant 2010; 25: 1200–1206.

    Article  PubMed  Google Scholar 

  2. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J . Renal function in newly diagnosed multiple myeloma: a demographic study of 1353 patients. The Nordic myeloma study Group. Eur J Haematol 1994; 53: 207–212.

    Article  CAS  PubMed  Google Scholar 

  3. Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on prognosis. Eur J Haematol 2000; 65: 175–181.

    Article  CAS  PubMed  Google Scholar 

  4. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

    Article  PubMed  Google Scholar 

  5. Dimopoulos MA, Terpos E . Renal insufficiency and failure. Hematology Am Soc Hematol Educ Program 2010; 2010: 431–436.

    Article  PubMed  Google Scholar 

  6. Ludwig H, Adam Z, Hajek R . Recovery of renal impairment by bortezomib-doxorubicin-dexamethasone (BDD) in multiple myeloma (MM) patients with acute renal failure: Results from an ongoing phase II study. Blood 2007; 110: 1054A (suppl 11; abstract 3603).

    Google Scholar 

  7. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976–4984.

    Article  PubMed  Google Scholar 

  8. Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG . Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20 year experience from a single center. Nephrol Dial Transplant 2010; 25: 419–426.

    Article  PubMed  Google Scholar 

  9. Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma; a multicenter study in 198 consecutive patient. Eur J Haematol 2009; 83: 519–527.

    Article  CAS  PubMed  Google Scholar 

  10. Lonial S, Cavenagh J . Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol 2009; 145: 681–708.

    Article  CAS  PubMed  Google Scholar 

  11. Korbet SM, Schwartz MM . Multiple myeloma. J Am Soc Nephrol 2006; 17: 2533–2545.

    Article  PubMed  Google Scholar 

  12. Sinclair D . IgD myeloma: clinical, biological and laboratory features. Clin Lab 2002; 48: 617–622.

    PubMed  Google Scholar 

  13. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR . Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900–2902.

    Article  CAS  PubMed  Google Scholar 

  14. Alyanakian MA, Abbas A, Delarue R, Arnulf B, Aucouturier P . Free immunoglobulin light chain serum levels in the follow up of patients with monoclonal gammopathies: correlation with 24 h urinary light chain excretion. Am J Hematol 2004; 75: 246–248.

    Article  PubMed  Google Scholar 

  15. Kantzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, bradwell AR et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437–1444.

    Google Scholar 

  16. Bradwell AR, Harding SJ, Fourrier NJ, Wallis GC, Drayson MT, Carr-Smith HD et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 2009; 55: 1646–1655.

    Article  CAS  PubMed  Google Scholar 

  17. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1684–1690.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kantzmann JA, Dispenzieri A, Kyle RA, Snyder MR, Pleval MF, Larson DR et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575–1578.

    Article  Google Scholar 

  19. Hutchison CA, Plant T, Drayson M, Cockwell P, Kontouri M, Basnayake K et al. Serum free light chain measurement aids in the diagnosis of myeloma patients with severe renal failure. BMC Nephrol 2008; 9: 11.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137: 240–243.

    Article  CAS  PubMed  Google Scholar 

  21. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum free light chain levels and their rapid reduction in response to therapy define an aggressive multiple subtype with poor prognosis. Blood 2007; 110: 827–832.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Perosa F, Minoia C, Favoino E, Prete M, Dammacco F . Staging multiple myeloma patients with active disease using serum levels of B2M-free HLA class 1 heavy chain together with IgM or platelet count. Blood Cells Mol Dis 2009; 42: 71–76.

    Article  CAS  PubMed  Google Scholar 

  23. Woodruff R, Sweet B . Multiple myeloma and massive Bence Jones proteinuria and preservation of renal function. Aust NZ J Med 1977; 7: 60–62.

    Article  CAS  Google Scholar 

  24. Solomon A, Weiss DT, Kattine AA . Nephrotoxic potential of Bence Jones proteins. N Engl M Med 1991; 324: 1845–1851.

    Article  CAS  Google Scholar 

  25. Blade J, Rosinol L . Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol 2005; 18: 635–652.

    Article  CAS  PubMed  Google Scholar 

  26. Ying WZ, Sanders PW . Mapping the binding domain of immunoglobulin light chains for Tamm–Horsfall protein. Am J Pathol 2001; 158: 1859–1866.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A et al. Longterm outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998; 13: 1438–1445.

    Article  CAS  PubMed  Google Scholar 

  28. Basnayake K, Cheung CK, Sheaff M, Fuggle W, Kamel D, Nakoinz S et al. Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. J Clin Pathol 2010; 63: 884–887.

    Article  PubMed  Google Scholar 

  29. Batuman V, Verroust PJ, Navar GL, Kaysen JH, Goda FO, Campbell WC et al. Myeloma light chains are ligand for cubulin (gp 280). Am J Physiol 1998; 27: F246–F254.

    Google Scholar 

  30. Klassen RB, Allen PL, Batuman VK, Hammond TG . Light chains are ligand for megalin. J Appl Physiol 2005; 98: 257–263.

    Article  CAS  PubMed  Google Scholar 

  31. Huang ZQ, Sanders PW . Localization of a single binding site for immunoglobulin chains on human Tamm–Horsfall glycoprotein. J Clin Invest 1997; 99: 732–736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Sengul S, Zwizinski C, Batuman V . Role of MAPK pathways in light chain induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol 2003; 284: F1245–F1254.

    Article  CAS  PubMed  Google Scholar 

  33. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004; 104: 40–42.

    Article  CAS  PubMed  Google Scholar 

  34. Guan S, el-Dahr S, Dipp S, Batuman V . Inhibition of Na-K-ATPase activity and gene expression by a myeloma light chain in proximal tubule cells. J Invest Med 1999; 47: 496–501.

    CAS  Google Scholar 

  35. Deret S, Denoroy L, Lamarine M, Vidal R, Mougenot B, Frangione B et al. Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Eng 1999; 12: 363–369.

    Article  CAS  PubMed  Google Scholar 

  36. Pozzi C, D’Amico M, Fogazzi GB, Curioni S, Ferario F, Pasquali S et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42: 1154–1163.

    Article  PubMed  Google Scholar 

  37. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482–1492.

    CAS  PubMed  Google Scholar 

  38. Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR et al. Longterm outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008; 23: 2052–2057.

    Article  CAS  PubMed  Google Scholar 

  39. Sanchorawala V . Light chain (AL)-amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol 2006; 1: 1331–1341.

    Article  PubMed  Google Scholar 

  40. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W et al. Toxic acute tubular necrosis following treatment with zolendronate (Zometa). Kidney Int 2003; 64: 281–289.

    Article  CAS  PubMed  Google Scholar 

  41. Durie BG, Kyle RA, Belch A, Besinger W, Blade J, Boccadoro M et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379–398.

    Article  PubMed  Google Scholar 

  42. Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G et al. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of the Italian Myeloma Network GIMEMA. Eur J Haematol 2009; 84: 223–228.

    Article  PubMed  Google Scholar 

  43. Kastritis E, Anagnostopoulous A, Roussou M, Gika D, Matsouka C, Barmparousi D et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dexamethasone containing regimens and the impact of novel agents. Haematologica 2007; 92: 546–549.

    Article  CAS  PubMed  Google Scholar 

  44. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma; presenting features and predictors of outcomes in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.

    Article  CAS  PubMed  Google Scholar 

  45. Tosi P, Zamagni E, Cellini C, Cangini D, Tacchetti P, Tura S et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004; 73: 98–103.

    Article  CAS  PubMed  Google Scholar 

  46. de la Rubia J, Roig M, Ibanez A, Garcia I, Vera JA, Aguilar C et al. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur J Haematol 2010; 85: 363–365.

    Article  PubMed  Google Scholar 

  47. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX Phase 3 study. Leukemia 2008; 22: 842–849.

    Article  CAS  PubMed  Google Scholar 

  48. Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulu M, Grapsa I et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010; 34: 1395–1397.

    Article  CAS  PubMed  Google Scholar 

  49. Ballester OF, Tummula R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC et al. High dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20: 653–656.

    Article  CAS  PubMed  Google Scholar 

  50. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  PubMed  Google Scholar 

  51. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I et al. High dose chemotherapy in light chain or light and heavy chain deposition diseases. Kidney Int 2004; 65: 642–648.

    Article  CAS  PubMed  Google Scholar 

  52. Lee CK, Zangari M, Barlogie B, Fassa SA, van Rhee F, Thertulien P et al. Dialysis-dependent renal failure in patients with myeloma can be reversed by high dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828.

    Article  CAS  PubMed  Google Scholar 

  53. Carlson K . Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation related toxicity and survival. Bone Marrow Transplant 2005; 35: 985–990.

    Article  CAS  PubMed  Google Scholar 

  54. Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006; 91: 1555–1558.

    CAS  PubMed  Google Scholar 

  55. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J et al. The clinical outcome and toxicity of high dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study. Br J Haematol 2006; 134: 385–390.

    Article  CAS  PubMed  Google Scholar 

  56. Hassoun H, Flombaum C, D’Agati VD, Rafferty BT, Cohen A, Klimek VM et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008; 42: 405–412.

    Article  CAS  PubMed  Google Scholar 

  57. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812–816.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143: 777–784.

    Article  PubMed  Google Scholar 

  59. Leung N, Gertz MA, Zeldenhurst SR, Rajkumar SV, Dispenzieri A, Fervenza FC et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and reduction of serum free light chains. Kidney Int 2008; 73: 1282–1288.

    Article  CAS  PubMed  Google Scholar 

  60. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4: 745–754.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Tanner GA, Evan AP . Glomerular and proximal tubular morphology after single nephron obstruction. Kidney Int 1989; 36: 1050–1060.

    Article  CAS  PubMed  Google Scholar 

  62. Hutchinson CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A et al. European trial of free light chain removal by extended hemodialysis in cast nephropathy (EuLITE): a randomized controlled trial. Trials 2008; 9: 55.

    Article  Google Scholar 

  63. Fish R, Pinney J, Jain P, Addison C, Jones C, Jayawardene S . The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 2010; 5: 1977–1980.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Harris E, Behren J, Samson D, Rahemtulla A, Russel NH, Byrne JL . Use of thalidomide in patients with myeloma and renal failure maybe associated with unexplained hyperkalemia. Br J Haematol 2003; 122: 160–161.

    Article  CAS  PubMed  Google Scholar 

  65. Mezzano SA, Barria M, Droguett MA, Burgos ME, Ardiles LG, Flores C et al. Tubular NF-kappa B and AP-1 activation in human proteinuric renal disease. Kidney Int 2001; 60: 1366–1377.

    Article  CAS  PubMed  Google Scholar 

  66. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM . Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma 2008; 49: 1108–1115.

    Article  CAS  PubMed  Google Scholar 

  67. Dimopoulous MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C et al. reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009; 9: 302–306.

    Article  Google Scholar 

  68. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 1844–1845.

    Article  Google Scholar 

  69. MacFarland R, Hard ML, Scarborough R, Badel K, Calandra G et al. A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. Biol Blood Marrow Transplant 2010; 16: 95–101.

    Article  PubMed  Google Scholar 

  70. Pinto V, Castelli A, Gaidano G, Conconi A . Safe and effective use of plerixafor plus G-CSF in dialysis dependent renal failure. Am J Hematol 2010; 85: 461–462.

    PubMed  Google Scholar 

  71. Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D et al. Safety of autotransplants with high dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947–952.

    CAS  PubMed  Google Scholar 

  72. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Rigg A et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001; 85: 325–332.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC et al. Longterm outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004; 43: 147–153.

    Article  PubMed  Google Scholar 

  74. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t (11;14)(q13;q32), t(4;14)(p16.3;q32) and −17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Kersting S, Verdonck LF . Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction. Biol Blood Marrow Transplant 2008; 14: 1312–1316.

    Article  PubMed  Google Scholar 

  77. Fudaba Y, Spitzer TR, Shaffer J, Kawai T, Fehr T, Delmonico F et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 2006; 6: 2121–2133.

    Article  CAS  PubMed  Google Scholar 

  78. Combined Bone Marrow Transplantation (BMT) and Renal Transplant for multiple myeloma (MM) with end stage renal disease (ESRD) NCT00854139 Clinical Trials.gov.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to B Wirk.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wirk, B. Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplant 46, 771–783 (2011). https://doi.org/10.1038/bmt.2011.8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.8

Keywords

This article is cited by

Search

Quick links